Marshall Wace LLP Sells 284,246 Shares of Embecta Corp. (NASDAQ:EMBC)

Marshall Wace LLP decreased its holdings in shares of Embecta Corp. (NASDAQ:EMBC - Free Report) by 77.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 83,789 shares of the company's stock after selling 284,246 shares during the quarter. Marshall Wace LLP owned about 0.14% of Embecta worth $1,730,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of EMBC. Walleye Capital LLC acquired a new position in Embecta during the fourth quarter valued at approximately $3,459,000. XTX Topco Ltd acquired a new position in shares of Embecta in the fourth quarter valued at approximately $630,000. Mariner LLC boosted its holdings in shares of Embecta by 21.6% in the fourth quarter. Mariner LLC now owns 20,018 shares of the company's stock valued at $413,000 after buying an additional 3,553 shares during the period. Barclays PLC lifted its position in shares of Embecta by 50.1% in the fourth quarter. Barclays PLC now owns 146,983 shares of the company's stock worth $3,035,000 after purchasing an additional 49,053 shares in the last quarter. Finally, Rockefeller Capital Management L.P. lifted its position in shares of Embecta by 9.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 98,756 shares of the company's stock worth $2,039,000 after purchasing an additional 8,684 shares in the last quarter. Institutional investors and hedge funds own 93.83% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Mizuho began coverage on shares of Embecta in a research report on Thursday, April 10th. They issued a "neutral" rating and a $15.00 price objective on the stock.

Insiders Place Their Bets

In other news, Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $16.38, for a total value of $50,778.00. Following the transaction, the director now directly owns 36,133 shares of the company's stock, valued at $591,858.54. This represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.42% of the company's stock.

Embecta Price Performance

NASDAQ EMBC traded up $0.09 on Thursday, hitting $12.28. 314,086 shares of the stock were exchanged, compared to its average volume of 455,877. The business's fifty day moving average is $12.60 and its 200 day moving average is $15.82. Embecta Corp. has a 52 week low of $10.00 and a 52 week high of $21.48. The company has a market capitalization of $713.89 million, a PE ratio of 12.28, a P/E/G ratio of 0.78 and a beta of 1.23.

Embecta (NASDAQ:EMBC - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. Analysts predict that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 4.89%. The ex-dividend date was Friday, February 28th. Embecta's dividend payout ratio (DPR) is currently 60.00%.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.